Enanta Pharmaceuticals, Inc. ENTA

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
60/100
Moderate

Ranked against 712 peers in Biotechnology

About Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, … Full ENTA analysis →

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.98), suggesting sticky customer base.
  • Cash Generation Consistent Cash generation is consistent (score 0.78), indicating reliable business model.

Key risks

  • ROIC Below WACC or Peers ROIC at 24.4th percentile suggests inefficient capital deployment.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
55
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where ENTA ranks in Biotechnology

Enanta Pharmaceuticals, Inc. ranks #105 of 713 scored companies in Biotechnology by moat score — the top 15%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
101 Instil Bio, Inc. TIL 60/100 Moderate
102 Tourmaline Bio, Inc. TRML 60/100 Moderate
103 Edgewise Therapeutics, Inc. EWTX 60/100 Moderate
104 Mirum Pharmaceuticals, Inc. MIRM 60/100 Moderate
105 Enanta Pharmaceuticals, Inc. ENTA 60/100 Moderate
106 Assembly Biosciences, Inc. ASMB 60/100 Moderate
107 CytomX Therapeutics, Inc. CTMX 60/100 Moderate
108 Mesoblast Limited MESO 60/100 Moderate
109 Travere Therapeutics, Inc. TVTX 60/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How ENTA scores on the Corporate Default defenses

Pricing Power

Score 55 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 72 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 86 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 33 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 66 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 55 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding ENTA's moat

What is Enanta Pharmaceuticals, Inc.'s moat score?

Enanta Pharmaceuticals, Inc. (ENTA) scores 60 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #105 of 713 scored companies in Biotechnology, the top 15%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (86/100) and its weakest is Capital Efficiency (33/100).

How does Enanta Pharmaceuticals, Inc. compare with other Biotechnology companies?

Enanta Pharmaceuticals, Inc. ranks #105 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Mirum Pharmaceuticals, Inc. (MIRM) at 60 just above it and Assembly Biosciences, Inc. (ASMB) at 60 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Enanta Pharmaceuticals, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Enanta Pharmaceuticals, Inc.?

The Corporate Default template measures 6 defenses, and ENTA scores: Pricing Power (55), Cost Advantage (72), Customer Stickiness (86), Capital Efficiency (33), Resilience (66), Scale & Market Position (55). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000